DIAL THEY WANT TO ONE 0.5. IT’S ALWAYS AVAILABLE ON OUR >>BRUCE HAMILTON: THE FEDERAL
GOVERNMENT WILL BEGIN SHIPPING
10’S OF THOUSANDS OF COURSES OF
RHYME DOES APPEAR THIS WEEKEND
WILL DECIDE WHERE THE MEDICINE
GOES. EARLY RESULTS FROM A
TRIAL SPONSORED BY THE NATIONAL
INSTITUTES OF HEALTH
AND A SEVERE WAS FOUND TO
SHORTEN THE DURATION OF ILLNESS
IN PATIENTS WITH SEVERE
COVID-19 BUT IT HAD NO
STATISTICALLY SIGNIFICANT
EFFECT ON WHETHER
PATIENTS DIED. US HEALTH IN
GAINESVILLE WAS ONE OF 68
CLINICAL TEST SITES AROUND THE
WORLD THAT TOOK PART IN THAT
STUDY HIS ONGOING TRIALS ARE
BEING HELD IN LED BY
US HEALTH. AMONG OTHERS
PRINCIPAL INVESTIGATOR DOCTOR
NICOLE OBEID WAS INVOLVED AND
SHE JOINS ME RIGHT HERE ON THE
MORNING SHOW GOOD MORNING.
>> GOOD MORNING. THANK YOU FOR
HAVING ME. >>BRUCE HAMILTON: NOW THIS IS THE FIRST STUDY TO SHOW A CLEAR
BENEFIT THE PATIENT SUFFERING
FROM NOVEL CORONAVIRUS.
>> THAT CORRECT VERY EXCITING.
>>BRUCE HAMILTON: DOCTOR FAUCI EMPHASIZED IT’S NOT A KNOCKOUT BUT IT DOES SHOW THAT A DRUG
CAN BLOCK THIS VIRUS.
>> YEAH THAT’S EXACTLY RIGHT IT IS THE FIRST ROUND TO SHOW A CLINICAL BENEFIT PEOPLE GOT OUT
OF THE HOSPITAL
WITH HER AND THE MORTALITY RATE
WAS LOWER FOR PEOPLE WHO
RECEIVED THE DRUG.
>>BRUCE HAMILTON: WHEN YOU
BEGAN THAT CLINICAL TESTING AND
IT STARTED SHOWING RESULTS.
WHAT WAS THE REACTION THERE IN
THE LAB.
>> THE THING IS THAT HE IS A BLINDED BETTY. YOU KNOW THE INVESTIGATORS THE
PATIENTS WE DON’T KNOW WHO WILL
GET THE DRUGS AND WHO DOESN’T.
NOW IT’S REALLY DIFFICULT TO
TELL.
WHAT LETTER NOT THE DRUG IS
WORKING IT ONLY AFTER
A NUMBER OF PEOPLE HAVE BEEN
INVOLVED IN THE STUDY ENDED
THAT THE STUDY IS AN BLINDED
AND THEN THE DATA ANALYST
EITHER ONE WHO CAN DETERMINED
AND LIKE AND WHICH GROUP THAT
WHETHER THERE WAS A BENEFIT
ACTUALLY THE INVESTIGATORS
NEVER KNOW WHETHER OR NOT THE
DRUG IS ACTUALLY WORKING.
>> SO LET’S TALK ABOUT
ITS EFFICACY IT’S NOT LIKE
TAKING AN ANTIBIOTIC FOR A
BACTERIAL INFECTION THAT WORKS
MORE KIND OF LIKE A I WOULD SAY
A CANCER DRUG IT LEADS TO
SOME IMPROVEMENT AND IT SHOWS
PROMISE.
>> THAT’S EXACTLY RIGHT.
I MEAN THE WAY IT WORKS IS
THAT IT STOP THE VIRUS FROM
BEING ABLE TO REPLICATE IT OUT.
SO IT’S A VIRUS CAN REPLICATE
IT CAN’T RIGHT IN THE BODY OR
REACHED VERY HIGH LEVEL AND
THAT’S HOW IT IS THERE TO
BENEFIT.
>> DOES THE RESEARCH CONTINUE
WITH THIS DRUG.
>> OH ABSOLUTELY THERE
IS A SECOND ARM OF THE TRIAL
WHICH WE HOPE IS GOING TO
START. NEXT WEEK. AND IN THAT
EVERYONE IS GOING TO GET READY
GUEST OF THE YEAR.
AND ABOUT HALF THE PEOPLE WILL
GET A
SECOND ROUND. IF A IF THERE’S A
BENEFIT TO HAVE IT TO DRUG
COMBINATION
RATHER THAN JUST YESTERDAY
ALONE THERE WERE REALLY EXCITED
TO BE PARTICIPATING IN THAT
NEXT PHASE OF
THE TRIAL.
>>BRUCE HAMILTON: SO IF
COMBINED WITH ANOTHER DRUG IS
IT POSSIBLE THAT IT COULD BE
EVEN MORE POTENT AND MORE
EFFECTIVE.
>> YES THAT IS EXACTLY WHAT THE
HOPE IS
THAT AGAIN WE NEED THE MEDICAL
TRIALS TO REALLY FIGURE OUT THE
ANSWER
TO THAT.
>>BRUCE HAMILTON: SO WHAT KIND
OF TIMEFRAME ARE WE LOOKING AT
BEFORE WE GET SOME YOU KNOW
THAT SOME CONCRETE INFORMATION.
>> THEY’LL BE OUT FOR START OF THE TRIAL WHERE RAND S THAT THERE WAS COMPARED TO BUT THE
BOW
THAT PART OF THE WHAT COMPETED
VERY
VERY QUICKLY, I’M A VERY
UNUSUAL FOR A STUDY LIKE THAT
COULD BE COMPLETED IN JUST A
FEW WEEKS
THAT BECAUSE THERE ARE THIS IS
AN INTERNATIONAL COLLABORATION.
SO THERE ARE MANY MANY PATIENTS
THAT WERE WERE ABLE TO BE IN
WROTE VERY VERY QUICKLY.
SO WE WOULD IT THAT IS THE
SECOND DAY. WE’LL ALSO THERE’S
IN A MATTER OF JUST A FEW
MONTHS
AS WELL.
>>BRUCE HAMILTON: AND BECAUSE
OF THE WORLDWIDE CONCERN WE
HAVE TO POINT OUT THAT THE FDA
KIND OF FAST TRACK THIS.
>> YEAH, YES, THEY DID THEY ISSUED IN AN EMERGENCY USE FOR
THE DRUG WHICH OBVIOUSLY IS REALLY NECESSARY AS WE ARE IN A AND THEN THE
RIGHT NOW.
>>BRUCE HAMILTON: SO THAT
DOESN’T WORRY YOU BECAUSE
THERE’S SOME YOU KNOW THERE’S
SOME SCIENTISTS WHO SAY YOU
KNOW I MAYBE WE SHOULD DO
MORE TESTING. DO YOU THINK
BECAUSE OF WHAT’S HAPPENING
WITH THE PANDEMIC
AND THE FACT THAT WE COULD BE
CONFRONTED WITH THIS VIRUS FOR
2 YEARS. THE FDA HAS TO CUT
THROUGH SOME OF THE RED TAPE.
>> NO I THINK WHAT IT WHAT WAS
UNIQUE ABOUT THE RIM DEATH OF
THEIR SITUATION IS THAT IT HAD
ALREADY BEEN THROUGH IT
AND IT SAFETY TRIAL
YEAR AGO. IN FACT IT WAS ONE
OF THE DRUG THAT WAS
INVESTIGATED TO SEE IF THAT
WOULD WORK AGAINST EBOLA SO WE
ALREADY HAVE A LARGE AMOUNT OF
SAFETY DATA. NO NO I’M NOT
CONCERNED THAT TO
BE RUSHED THROUGH OUR THAT ANY
CORNERS ARE BEING CUT IT JUST
THAT WE FORTUNATELY ALREADY
HAVE A LOT OF INFORMATION ABOUT
ITS SAFETY.